RAPT Therapeutics (NASDAQ:RAPT) had its target price cut by stock analysts at BMO Capital Markets from $51.00 to $45.00 in a research report issued on Tuesday, The Fly reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price would indicate a potential upside of 177.44% from the stock’s previous close.
Several other research firms have also recently weighed in on RAPT. Cantor Fitzgerald raised their price target on RAPT Therapeutics from $37.00 to $51.00 and gave the company an “overweight” rating in a report on Monday, July 27th. Zacks Investment Research lowered RAPT Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 12th. BidaskClub lowered RAPT Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. HC Wainwright decreased their price target on RAPT Therapeutics from $42.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, ValuEngine raised RAPT Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $38.86.
Shares of NASDAQ RAPT traded down $0.19 during trading on Tuesday, hitting $16.22. The company had a trading volume of 13,315 shares, compared to its average volume of 174,332. The stock has a 50 day simple moving average of $32.94 and a 200 day simple moving average of $26.68. RAPT Therapeutics has a 12 month low of $10.52 and a 12 month high of $51.21. The firm has a market capitalization of $401.54 million and a P/E ratio of -1.15.
RAPT Therapeutics (NASDAQ:RAPT) last released its earnings results on Monday, November 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.04). Equities analysts anticipate that RAPT Therapeutics will post -2.12 EPS for the current fiscal year.
In other RAPT Therapeutics news, insider William Ho sold 1,000 shares of RAPT Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $26.24, for a total transaction of $26,240.00. Following the completion of the sale, the insider now directly owns 67,858 shares of the company’s stock, valued at approximately $1,780,593.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Karen C. Lam sold 2,022 shares of RAPT Therapeutics stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $28.14, for a total value of $56,899.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 2,700 shares of company stock valued at $80,070 and have sold 637,932 shares valued at $19,878,014. Insiders own 31.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. ExodusPoint Capital Management LP purchased a new position in shares of RAPT Therapeutics in the 3rd quarter valued at $545,000. Charles Schwab Investment Management Inc. increased its holdings in shares of RAPT Therapeutics by 26.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 65,397 shares of the company’s stock valued at $2,106,000 after acquiring an additional 13,641 shares during the period. Arrowstreet Capital Limited Partnership purchased a new position in shares of RAPT Therapeutics in the 3rd quarter valued at $376,000. State Street Corp increased its holdings in shares of RAPT Therapeutics by 4.7% in the 3rd quarter. State Street Corp now owns 186,328 shares of the company’s stock valued at $6,000,000 after acquiring an additional 8,379 shares during the period. Finally, TD Asset Management Inc. increased its holdings in shares of RAPT Therapeutics by 116.5% in the 3rd quarter. TD Asset Management Inc. now owns 57,970 shares of the company’s stock valued at $1,867,000 after acquiring an additional 31,200 shares during the period. 58.04% of the stock is owned by institutional investors and hedge funds.
About RAPT Therapeutics
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors.
Further Reading: How to start trading in the forex market?
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.